Abstract Body

Background: Mitochondria carry their genome and are critical in providing energy for cellular processes in the central nervous system (CNS). Damage to mitochondrial DNA (mtDNA) is associated with many neurodegenerative diseases. HIV infection and methamphetamine (METH) abuse, a common comorbidity, can cause damage to mtDNA and subsequently lead to neurocognitive morbidity. Here we evaluated the role of mitochondrial injury in relation to HIV infection and METH use.

Methods: We collected brain tissue of parietal and frontal lobes from HIV-infected individuals with evidence of METH use (n=6), HIV-infected individuals with no METH use (n=4) and HIV-negative controls (n=7) from the National NeuroAids Tissue Consortium. DNA was extracted from gray and white matter from each lobe. We quantified mtDNA levels and mitochondria carrying the “common deletion” as a measurement of mitochondrial injury in relation to a cellular control using droplet digital PCR (ddPCR). Measures of mtDNA and “common deletion” were evaluated in relation to clinical Global Deficiency Score and other clinical variables.

Results: Our examination of all groups together found that levels of “common deletion” increased with age in the parietal white (r=0.75, p=0.0005) and grey matter (r=0.60, p=0.01), and frontal white (r=0.43, p=0.08) and gray matter (r=0.55, p=0.02). After excluding the three participants with Alzheimer’s Disease, one per group, which is known to increase the relative proportion of “common deletion” in brain tissue, we found that a higher relative proportion of mtDNA with the “common deletion” was associated with worse neurocognitive impairment (r=0.99, p=0.003) only in the parietal white matter of HIV-infected individuals not using METH. Interestingly, in the parietal white matter of HIV-infected METH users, a higher relative proportion of “common deletion” was associated with higher CD4 counts, and inversely with degree of impairment (r=-0.86, p=0.06).

Conclusions: While an increased proportion of mtDNA carrying the “common deletion” was associated with increasing neurocognitive impairment in HIV-infected individuals as expected, METH use appeared to provide a protective effect. METH has been shown to increase autophagy and be neuroprotective at low doses. Further work is required to explore the role of mitochondrial injury in HIV-infected individuals and the effects of METH use on this damage.